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ABSTRACT Staphylococcus aureus is a major cause of morbidity and mortality
worldwide. S. aureus colonizes 20 to 80% of humans at any one time and causes a
variety of illnesses. Strains that are resistant to common antibiotics further compli-
cate management. S. aureus vaccine development has been unsuccessful so far,
largely due to the incomplete understanding of the mechanisms of protection
against this pathogen. Here, we studied the role of different aspects of adaptive im-
munity induced by an S. aureus vaccine in protection against S. aureus bacteremia,
dermonecrosis, skin abscess, and gastrointestinal (GI) colonization. We show that, de-
pending on the challenge model, the contributions of vaccine-induced S. aureus-
specific antibody and Th1 and Th17 responses to protection are different: antibodies
play a major role in reducing mortality during S. aureus bacteremia, whereas Th1 or
Th17 responses are essential for prevention of S. aureus skin abscesses and the
clearance of bacteria from the GI tract. Both antibody- and T-cell-mediated mecha-
nisms contribute to prevention of S. aureus dermonecrosis. Engagement of all three
immune pathways results in the most robust protection under each pathological
condition. Therefore, our results suggest that eliciting multipronged humoral and
cellular responses to S. aureus antigens may be critical to achieve effective and com-
prehensive immune defense against this pathogen.
IMPORTANCE S. aureus is a leading cause of healthcare- and community-associated
bacterial infections. S. aureus causes various illnesses, including bacteremia, meningi-
tis, endocarditis, pneumonia, osteomyelitis, sepsis, and skin and soft tissue infections.
S. aureus colonizes between 20 and 80% of humans; carriers are at increased risk for
infection and transmission to others. The spread of multidrug-resistant strains limits
antibiotic treatment options. Vaccine development against S. aureus has been unsuc-
cessful to date, likely due to an inadequate understanding about the mechanisms of
immune defense against this pathogen. The significance of our work is in illustrating
the necessity of generating multipronged B-cell, Th1-, and Th17-mediated responses
to S. aureus antigens in conferring enhanced and broad protection against S. aureus
invasive infection, skin and soft tissue infection, and mucosal colonization. Our work
thus, provides important insights for future vaccine development against this patho-
gen.
KEYWORDS B-cell responses, Staphylococcus aureus, T-cell immunity, adaptive
immunity, vaccines
Staphylococcus aureus is a leading cause of community- and healthcare-associatedbacterial infections and postsurgical wound infections (1–4). Skin and soft tissue
infections (SSTIs) are a common type of community-acquired S. aureus infection, which
can be recurrent in many individuals (5, 6). S. aureus also causes severe invasive disease,
such as bacteremia, meningitis, endocarditis, osteomyelitis, pneumonia, sepsis, and
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toxic shock syndrome (4, 7). S. aureus bacteremia is associated with high mortality (20
to 40% in adults) despite appropriate antibiotic treatment (8). S. aureus colonizes about
20 to 80% of the human population at any given time, providing a reservoir for
subsequent infection and transmission (9–12). The rapid increase of S. aureus strains
that are resistant to multiple antibiotics, such as methicillin-resistant S. aureus (MRSA)
and vancomycin-intermediate and -resistant strains (VISA and VRSA, respectively), in
both community- and hospital-acquired infections (13–15), has complicated the man-
agement of these infections.
The development of S. aureus vaccines has been challenging. For diseases caused by
many bacterial pathogens, such as Streptococcus pneumoniae, Haemophilus influenzae
type b, and Neisseria meningitidis, antibodies to polysaccharide (PS) or protein antigens,
generated by either natural exposure or immunization, are highly protective (16, 17). A
similar approach has been attempted for S. aureus vaccine development but yielded
disappointing results so far. While multiple candidates targeting various S. aureus PSs
and/or proteins have shown promise in preclinical studies, no antibody-based S. aureus
vaccine (via either passive or active immunization) has succeeded in clinical trials
(18–23). This failure has then led to further deliberation about the immunological
requirements for effective S. aureus defense. Indeed, despite the suggestion that
individuals with high-titer preexisting anti-S. aureus antibody may have better prog-
nosis during S. aureus bacteremia and sepsis (24–26) (while S. aureus-specific T-cell
immunity in those individuals and its contribution to protection were not examined in
the same studies), no direct correlation has ever been established between the level of
anti-S. aureus antibody and the prevention of S. aureus infection or colonization (18,
27–29), suggesting that whatever protective role antibodies may play is insufficient to
effectively prevent S. aureus pathogenesis. Furthermore, a growing body of literature
now implicates the importance of cellular immunity in innate and possibly acquired S.
aureus resistance. Indeed, compared to the general population, HIV-infected individuals
have significantly higher rates of S. aureus SSTI, bacteremia, endocarditis, and coloni-
zation (30–33). A recent study suggests that the decreased S. aureus-specific Th1
immunity may be part of the reason for the increased incidence of MRSA SSTI in HIV
patients (34). Another classic immunodeficiency associated with frequently recurrent S.
aureus skin and lung infection is Job’s syndrome (i.e., hyper-immunoglobulin E syn-
drome), which features in defective interleukin-17 (IL-17) production (and thus, Th17
immunity) due to mutations in the stat3 gene (35, 36). In addition to these observations
in humans, studies in mice have also pointed to the importance of innate and memory
T cells in resistance to S. aureus. Lin et al. showed that deficiency in gamma interferon
(IFN-) production enhanced mouse susceptibility to S. aureus bloodstream infection
(37). Brown and coworkers reported that adoptive transfer of S. aureus-specific, memory
Th1 cells protected naive mice against S. aureus peritoneal infection (38). A study in
severe combined immunodeficiency (SCID) mice showed that, following immunization
with the S. aureus antigen IsdB, Th17 cells were critical for protection against lethal S.
aureus sepsis challenge (39). Furthermore, previous exposure to S. aureus protects mice
against recurrent dermonecrosis in an antibody- and Th17-dependent fashion (40). The
production of IL-17 and IL-22 by innate immune cells was also found to be critically
important in the control of S. aureus nasal carriage (41–43). These observations there-
fore suggest that host defense against S. aureus may require the involvement of several
immune factors rather than humoral responses alone.
In this work, we investigate the respective roles of vaccine-induced S. aureus-specific
humoral and cellular immunity in acquired protection against S. aureus under various
pathological conditions, including invasive infection, SSTI (dermonecrosis and abscess),
and mucosal colonization in mice. Our results show that depending on the type of S.
aureus challenge, protection is mediated by different immune pathways, including
antibody, Th1 or Th17 response, a combination of the two, or all of the above. Thus,
compared to an antibody-based strategy, an approach that elicits all three types of
immune responses to S. aureus antigens confers more robust and broad protection in
mice against both S. aureus infection and carriage.
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Generation of S. aureus-specific immune responses. To generate different adap-
tive immune responses to S. aureus antigens, we immunized C57BL/6 mice with two
antigen formulations. The first formulation consisted of a mixture of six S. aureus
proteins (referred to as S. aureus mix below), including -hemolysin (Hla) toxoid (see
Fig. S1 in the supplemental material), clumping factors A (ClfA) and B (ClfB), serine-
aspartate repeat protein D (SdrD), and iron-regulated surface proteins A (IsdA) and B
(IsdB) (see Fig. S2 in the supplemental material). When administered with aluminum
hydroxide adjuvant (Alum), S. aureus mix induces robust antibodies, but no measurable
cellular responses to the included antigens (Fig. 1A and B, SA mix). The second
formulation consisted of a macromolecular complex (called the multiple antigen
presenting system [MAPS] complex) in which the same six S. aureus proteins were
coupled to a biotinylated polysaccharide scaffold via affinity interaction between
rhizavidin (rhavi) and biotin molecules (44) (see Fig. S2 in the supplemental material).
As shown previously with other antigens (44), immunization of mice with S. aureus
MAPS complexes and Alum induced not only a high level of antibodies, but also
antigen-specific adaptive cellular responses, as indicated by robust production of IFN-
and IL-17A upon ex vivo stimulation of peripheral blood with the target protein
antigens (Fig. 1A and B, SA MAPS). Further analysis indicated that both cytokines are
primarily produced by CD4 T helper cells (Fig. 1C), representing Th1 and Th17
responses.
FIG 1 Generation of S. aureus-specific immune responses. C57BL/6 mice (n  10 per group) received
three subcutaneous immunizations with adjuvant alone (Alum), or Alum-adjuvanted S. aureus protein
(SA) mix or S. aureus MAPS (SA MAPS) vaccine (30 g of total protein content per dose). (A) Antigen
(Ag)-specific IgG antibodies were measured 2 weeks after the third immunization. Antibody titers are
expressed in arbitrary units (a.u.) related to a reference serum (as described in Materials and Methods).
Bars represent geometric means  95% confidence interval (CI). (B) IFN- and IL-17A production after ex
vivo stimulation of peripheral blood cells of immunized mice with a mixture of purified S. aureus proteins.
Bars represent geometric means  95% CI. Statistical analysis was performed using nonparametric
one-way ANOVA (Dunn’s multiple comparison test) between indicated groups. N.S, not significant. (C)
IFN- and IL-17A production after ex vivo stimulation of splenocytes isolated from an Alum-immunized
mouse with S. aureus proteins in the absence or presence of CD4 or CD8 T cells purified from the
spleen of an S. aureus MAPS-immunized mouse.
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Protection against S. aureus is mediated by different adaptive immune re-
sponses. Acquired protection mediated by anti-S. aureus immune responses was
evaluated in four challenge models. For invasive infection, we used a bacteremia
model, in which mice were injected intravenously with 2  107 CFU of S. aureus (ATCC
29213 strain, type 5 capsule-expressing). Protection was evaluated by comparing
survival curves over 14 days (Fig. 2A). For SSTI, we used two different models. In the
dermonecrosis model, subcutaneous inoculation of mice with 1  107 CFU of S. aureus
(USA300 TCH959 strain) leads to severe skin damage and the formation of necrotic
lesions (45). Protection was assessed with respect to the overall incidence of lesions
(Fig. 2B, symbol key) and the surface area of the dermonecrotic lesion in those animals
that were affected (Fig. 2B, curves). In the skin abscess model, mice were infected with
a lower inoculum (2  105 to 5  105 CFU), which induces enclosed subdermal
abscesses with minimal skin breakdown (45). Protection was assessed by comparing
densities of S. aureus recovered from abscesses dissected 4 days postinfection (Fig. 2C).
Finally, S. aureus gastrointestinal (GI) colonization was examined following intranasal
inoculation of mice with 5  107 CFU of the USA300 LACStrep strain; this results in stable
GI colonization in naive mice for 21 days (see Fig. S3 in the supplemental material).
FIG 2 Acquired protection against S. aureus invasive disease, SSTI, and GI colonization. Mice (n  10 per group)
were immunized as described previously. Three weeks after the last immunization, mice were challenged in models
of bacteremia (A), dermonecrosis (B), skin abscess (C), and GI colonization (D). (A) Survival curves after infection.
Statistical analysis was performed by the Mantel-Cox test in comparison to the Alum group. (B) The incidence of
dermonecrosis in each group is indicated in the symbol key. Individual curves show progression of lesions over
time in those animals that developed dermonecrosis postinoculation. Symbols represent means  standard errors
of the means (SEM). Statistical analysis was performed using Fisher’s exact test (for incidence) or two-way ANOVA
(for lesion size) in comparison to the Alum group. (C) Bacterial CFU recovered from skin abscesses 4 days
postinoculation. Each symbol represents one mouse, and lines indicate medians. The dashed line indicates one-half
of the lower detection limit (22.5 CFU). Statistical analysis was performed using nonparametric one-way ANOVA
(Dunn’s multiple comparison test) between indicated groups. (D) Bacterial CFU recovered from feces 1 day (D1) and
7 days (D7) postinoculation. Each symbol represents one mouse, and lines indicate medians. The dashed line
indicates one-half of the lower detection limit (40 CFU). Statistical analysis was performed using nonparametric
one-way ANOVA (Dunn’s multiple comparison test) between indicated groups.
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Protection was assessed by comparing bacterial densities in feces at indicated time
points postinoculation (Fig. 2D).
We found that mice that developed only anti-S. aureus antibodies (i.e., those in the
S. aureus mix group) were significantly protected in two of the four models, with
reduced mortality following intravenous (i.v.) infection (40 versus 80% in the control
group [Fig. 2A]) and a decreased incidence of lesions in the dermonecrosis model (30%
versus 100% in the control group [Fig. 2B]). However, with respect to skin abscess or GI
colonization, they were equally susceptible as the control group (Fig. 2C and D). In
contrast, mice that developed both antibody and cellular responses to S. aureus
antigens (i.e., those in the S. aureus MAPS group) demonstrated broad resistance to all
four S. aureus challenges, including bacteremia (reduced mortality and delayed disease
onset) and dermonecrosis (reduced incidence and symptoms of lesions) (Fig. 2A and B),
as well as in the abscess and GI colonization models. In the skin abscess model, 7 out
of 10 S. aureus MAPS-vaccinated mice had no detectable abscess (and no recoverable
bacteria) 4 days postinfection, whereas mice in the control group or the S. aureus mix
group all had skin abscesses and recoverable CFU ranging from 103 to 106 (Fig. 2C). In
the GI colonization model, with an initial inoculation density of 105 CFU per g of feces
(median, 1 day postchallenge), S. aureus MAPS-vaccinated mice were able to rapidly
clear bacteria from the GI tract: S. aureus could not be detected in 2 out 10 mice 7 days
postchallenge, and the group had a median bacterial density of 641 CFU per g of feces,
40- to 50-fold lower than bacterial densities at the same time point in the control group
or the S. aureus mix group (Fig. 2D).
Differential roles of antigen-specific antibodies and Th1 and Th17 responses in
protection against S. aureus. The results above suggest that adaptive humoral or
cellular responses may contribute differentially to protection against S. aureus infec-
tions or colonization. Next, we dissected the role of each immune pathway in individual
challenge models.
The contribution of antibodies was evaluated by passive immunization. We ob-
tained sera from rabbits pre- or post-S. aureus MAPS vaccination (see Fig. S4 in the
supplemental material) and passively transferred these to mice before challenge in
each model. In the bacteremia model, mice that received postimmune sera had
significantly lower mortality at 14 days postinfection compared to the control group
(50% versus 90%, P  0.0007) (Fig. 3A). In a separate experiment, we sacrificed the mice
20 h postinfection and measured bacterial burden in their kidneys: as shown in Fig. S5
in the supplemental material, the group that received postimmune sera had signifi-
cantly lower CFU than the control group, suggesting that antibody-mediated bacterial
clearance contributes to protection in this model. Passive immunization also effectively
mitigated (but did not fully prevent) S. aureus dermonecrosis, resulting in reduced
lesion size (Fig. 3B). However, the presence of S. aureus-specific antibodies did not
provide any protection against either skin abscess or GI colonization (Fig. 3C and D).
The contribution of cellular responses was studied in antibody-deficient (MT/)
mice. Vaccination of MT/ mice with S. aureus MAPS induced Th1 and Th17
responses to S. aureus antigens without detectable humoral responses (Fig. 4A) and
conferred significant protection in three models: compared to the control group, S.
aureus MAPS-vaccinated MT/ mice had smaller lesions during dermonecrosis chal-
lenge (P  0.03 [Fig. 4C]), significantly reduced abscess formation (P  0.0001
[Fig. 4D]), and accelerated clearance of S. aureus carriage from the GI tracts postcolo-
nization (P 	 0.0001 [Fig. 4E]). In the case of S. aureus bacteremia, the presence of only
cellular responses did not provide significant protection (Fig. 4B).
Therefore, we conclude from these experiments that humoral and cellular responses
serve as complementary mechanisms in providing protection against different S. aureus
challenges: antibody-mediated mechanisms confer protection against S. aureus bacte-
remia, but are ineffective in prevention of S. aureus skin abscess or colonization, against
which antigen-specific cellular responses are both essential and sufficient. Furthermore,
humoral and cellular responses, collectively, confer optimal protection against S. aureus
dermonecrosis.
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As immunization with S. aureus MAPS construct induces at least two types of cellular
responses, Th1 and Th17 responses, we sought to further dissect their respective
contributions to protection in the abscess or GI colonization model, using cytokine
supplementation or depletion approaches. To evaluate the role of Th1 or Th17 immu-
nity against skin abscesses, we infected naive mice with S. aureus inocula that were
premixed with recombinant mouse IFN-, IL-17A, IL-22, or a combination of different
cytokines. The presence of recombinant cytokine(s) did not affect the viability of S.
aureus in the inoculum (see Fig. S6 in the supplemental material). Mice in the control
group were infected with S. aureus mixed with buffer vehicle: 9 out of 10 animals (90%)
developed skin abscesses with a median bacterial density of 104 CFU (Fig. 5A,
phosphate-buffered saline [PBS]). In contrast, supplementation of the inoculum with
either IFN- or IL-17A but not IL-22 during infection was able to lower the incidence of
abscess to 50% and reduce the median bacterial burden to 55 or 208 CFU, whereas
coadministration of both IFN-  and IL-17A resulted in almost complete protection
(9/10 mice were free of abscess 4 days postinfection) (Fig. 5A). This result was further
confirmed by cytokine depletion in S. aureus MAPS-vaccinated animals during abscess
challenge, which showed that S. aureus MAPS-induced protection was only slightly
impacted by depletion of either IFN- or IL-17, but was significantly attenuated when
antibodies to both cytokines were administered (Fig. 5B). We noticed that protection
was not completely abolished by administration of anti-IFN- and anti-IL-17 antibodies.
FIG 3 Evaluation of antibody-mediated protection against S. aureus in different models. Mice (n  10
per group) received 200 l of pre- or postimmune rabbit sera 1 day prior to S. aureus inoculation. (A)
Survival curves during S. aureus bacteremia. Differences between groups were analyzed by the Mantel-
Cox test. (B) Size of lesions at different time points postinoculation in the dermonecrosis model. Symbols
represent mean  SEM. Differences between the Alum and S. aureus protein (SA) mix groups or Alum
and S. aureus (SA) MAPS groups were compared using two-way ANOVA. (C) Bacterial CFU recovered
post-S. aureus inoculation in the abscess model. Each symbol represents one animal, and lines indicate
medians. A dashed line indicates one-half of the lower detection limit (22.5 CFU). Statistical analysis was
performed using the Mann-Whitney U test (two tailed). (D) Bacterial CFU recovered from feces 1 day (D1)
and 7 days (D7) postinoculation. Each symbol represents one mouse, and lines indicate the median. A
dashed line indicates one-half of the lower detection limit (40 CFU). Statistical analysis was performed
using the Mann-Whitney U test (two tailed).
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This result may be due to an insufficient concentration of administered antibodies
and/or the inability of antibodies to effectively access and neutralize locally produced
cytokines at the site of abscess formation. Taken together, these results suggest that
either Th1 or Th17 responses to these antigens may be sufficient to prevent S. aureus
skin abscess.
In contrast to what was observed in the abscess model, when a cytokine depletion
was performed in the GI colonization model we found that depletion of either IFN- or
IL-17 completely abolished S. aureus MAPS-induced protection in mice, suggesting that
the clearance of S. aureus carriage may require both Th1- and Th17-mediated immune
responses (Fig. 6).
DISCUSSION
Humoral immunity and cellular immunity are two important arms of host defense
against microbial invasions. While the strategy of generating antibodies has been
widely used in bacterial vaccinology and highly successful in the prevention of several
diseases, there is a growing recognition that adaptive cellular responses, such as Th1
and Th17 responses, may play a critical role in protection against infection and/or
colonization by certain extracellular bacterial pathogens (46). Studies in mice showed
that Th17 memory responses specific to S. pneumoniae could facilitate nasopharyngeal
clearance (47, 48) and provide cross-serotype protection against invasive pneumococ-
cal disease (49). Moreover, a recent work using a nonhuman primate model revealed an
important role of Th17/Th1 memory generated by the whole-cell pertussis vaccine in
FIG 4 Evaluation of S. aureus MAPS-induced protection against S. aureus infection and colonization in
antibody-deficient mice. MT/ mice (n  10 per group) were immunized three times with adjuvant alone
(Alum) or S. aureus (SA) MAPS. (A) Antigen-specific antibody and cellular responses were examined 2 weeks
after the last immunization. (B) Survival curves following intravenous infection. Differences between groups
were analyzed by the Mantel-Cox test. (C) Sizes of lesions at different time points postinoculation in the
dermonecrosis model. Symbols represent the mean  SEM. Differences between groups were analyzed
using two-way ANOVA. (D) Bacterial CFU recovered from skin abscesses. Lines indicate medians. Statistical
analysis was performed using the Mann-Whitney U test (two tailed). (E) Bacterial CFU in feces 1 day and 7
days postinoculation. Lines indicate medians. Statistical analysis was performed using the Mann-Whitney U
test (two tailed).
Mechanisms of Acquired Immunity against S. aureus ®
September/October 2018 Volume 9 Issue 5 e01949-18 mbio.asm.org 7
 on O








protection against colonization, transmission, and secondary infection of Bordetella
pertussis and hypothesized that the absence (or significant reduction) of such cellular
responses induced by current acellular pertussis vaccines may be an important reason
for their inferior efficacy (50).
The development of S. aureus vaccines has been extremely challenging. In addition
to the wide variety of diseases for which the organism is responsible, S. aureus is a
common colonizer of healthy individuals, with a concomitant risk of transmission and
skin and soft tissue autoinoculation. It is unclear whether natural immunity to S. aureus
truly occurs: unlike for other common bacterial pathogens such as pneumococcus,
Haemophilus influenzae type b, and meningococcus, there is no clear age association
with S. aureus infections, and recurrence is not uncommon. These findings suggest that
the naturally induced immune responses to S. aureus infections, antibodies (51–54) and
T-cell responses (38, 55), are likely insufficient to protect against this pathogen. Previous
preclinical studies of S. aureus vaccine candidates had primarily focused on invasive
infection models in which antibodies to specific S. aureus polysaccharide and/or protein
antigens were found to be highly protective. However, the failure of all antibody-based
vaccine candidates in clinical trials to date could be interpreted as indicating that
immune mechanisms other than antibodies may be required to effectively reduce or
prevent S. aureus pathogenesis in humans. Another important implication is that
preclinical evaluation using different challenge models, including invasive infection,
SSTI, and mucosal colonization models, in which protection is mediated via various
immune factors (e.g., antibodies and Th1 and/or Th17 responses) (38, 40, 43), may be
important to properly assess the potential of vaccine candidates.
In this work, we elucidate the importance of vaccine-induced S. aureus-specific
antibody and Th1 and Th17 responses in conferring comprehensive protection against
S. aureus infection and colonization. Our results show that different immune responses
mediate protection depending on the site and type of S. aureus infection/colonization.
For instance, antibodies protect mice against S. aureus i.v. infection, and to some extent,
dermonecrosis, but are ineffective in the prevention of skin abscess or GI colonization,
whereas antigen-specific cellular (Th1 and Th17) responses are critically involved in
FIG 5 Role of Th1 and Th17 responses in prevention of S. aureus skin abscess. (A) Supplementation with
recombinant mouse IFN- or IL-17A (but not IL-22) mitigates S. aureus abscess formation in naive mice. Mice (n 
8 to 10 per group) were injected subcutaneously with 2.5  105 CFU of USA300 strain mixed with PBS (vehicle
control), rIFN- (1 g per mouse), rIL-17A (0.9 g per mouse), rIL-22 (1 g per mouse), a combination of rIFN- and
IL-17A, or all three cytokines. Skin abscesses were dissected 4 days postinoculation for bacterial CFU quantification.
Lines indicate medians. Statistical analysis was performed using nonparametric one-way ANOVA (Dunn’s multiple
comparison test) in comparison to the PBS group. (B) Depletion of both IFN- and IL-17A significantly attenuated
S. aureus (SA) MAPS-mediated protection against abscess formation. Mice (n  10) were immunized three times
with Alum or S. aureus MAPS before skin abscess challenge. Antibodies against IFN- and/or IL-17A or the isotype
control were administered 1 day prior to inoculation and also on the day of inoculation. Lines indicate medians.
Statistical analysis was performed between the indicated groups using the Mann-Whitney U test (two tailed).
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protection against SSTI (dermonecrosis and abscess) and GI carriage but do not provide
significant protection following i.v. infection. In this light, it is not surprising that we find
optimal protection against S. aureus when all three immune pathways are engaged
during vaccination. Therefore, our data strongly suggest that vaccine strategies aiming
to induce multipronged B- and T-cell responses to S. aureus antigens may be critical to
prevent different aspects of S. aureus pathogenesis and thus provide comprehensive
protection against this pathogen.
MATERIALS AND METHODS
Mouse and bacterial strains. Wild type and MT/ C57BL/6 mice were purchased from Jackson
Laboratories. S. aureus strains USA300 (TCH959) and ATCC 29213 were purchased from ATCC. The
USA300 LAC (JE2) strain was kindly provided by BEI (56). The streptomycin-resistant USA300 LAC (JE2)
strain (USA300 LACstrep) was obtained by spontaneous mutation after culturing the parent strain on a
blood agar plate containing 0.5 g/liter streptomycin.
Ethics statement. All procedures involving mice were approved by the Boston Children’s Hospital
Animal Care and Use Committee (IACUC protocol no. 16033133), following the National Institutes of
Health guidelines for animal housing and care.
Cytokines and antibodies. Recombinant mouse IFN-, IL-17A, and IL-22 were purchased from R&D
systems. Cytokines were reconstituted at 100 mg/ml in PBS and then diluted with PBS to the appropriate
concentration during infection. Anti-mouse IFN- (clone R4-6A2), anti-mouse IL-17A (clone 17F3), and the
corresponding isotype control antibodies were purchased from Bioxcell. For cytokine depletion in the
skin abscess model, mice received 300 g of anticytokine antibodies or isotype control via intraperitoneal
injection 1 day prior to infection and another 300 g via subcutaneous injection the same day of
infection but at a distinct location from the infection site. For cytokine depletion in the GI colonization
model, mice received 300 g of the indicated antibodies via intraperitoneal injection 1 day prior to
inoculation and on days 1, 5, and 8 postinoculation.
Cloning and purification of S. aureus antigens. DNA sequences encoding ClfA (positions 221 to
559), ClfB (203 to 542), SdrD (246 to 682), IsdA (47 to 324), IsdB (48 to 477), or Hla (27 to 319) were
amplified from S. aureus genomic DNA (USA300 TCH959 strain) via PCR and then cloned into a pET-21b
vector. A nonhemolytic toxoid of Hla was generated by substitution of residues Asp-Arg-Asp (209 to 211)
to Ala-Ala-Ala using PCR. For rhizavidin fusion proteins, DNA sequences encoding the above S. aureus
FIG 6 Role of Th1 and Th17 responses in clearance of S. aureus GI colonization. Mice (n  10) were
immunized three times with Alum or S. aureus (SA) MAPS prior to challenge in the GI colonization model.
Antibodies against IFN- and/or IL-17A or the isotype control were administered 1 day prior to inocu-
lation and also on days 1, 5, and 8 postinoculation. Feces were collected on days 1, 7, 11, and 14
postinoculation for CFU analysis. Lines represent medians. Statistical analysis was performed using
two-way ANOVA.
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antigens were inserted at the 3= end of the gene encoding the rhizavidin moiety in a pET-21b vector. All
constructs were transformed into the E. coli BL21(DE3) strain for expression under isopropyl--D-
thiogalactopyranoside (IPTG) induction. His-tagged recombinant proteins were purified using nitrilotri-
acetic acid (NTA) affinity chromatography (Qiagen) followed by size exclusion chromatography using a
Superdex 200 column (GE Healthcare Life Sciences). Purified proteins were stored at 80°C until use.
Preparation of S. aureus MAPS complexes. Type-1 pneumococcal capsular polysaccharide was
purchased from ATCC and used as the scaffold for S. aureus MAPS constructs. The polysaccharide was
biotinylated using CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) as the activation re-
agent as described previously (44). S. aureus MAPS complex was assembled by incubation of biotinylated
polysaccharide with a mixture of rhizavidin fusions of S. aureus antigens (at equal molarity) at room
temperature overnight. The input ratio of total proteins to polysaccharide was 3:1 (wt/wt). The assembled
complex was isolated by size exclusion chromatography and concentrated by ultrafiltration. The protein
concentration of S. aureus MAPS complexes was measured using a bicinchoninic acid (BCA) protein assay
kit (Thermo Scientific). The incorporation of S. aureus antigens was examined on a reduced SDS-PAGE gel.
Immunization and infection. All vaccines were formulated the day prior to immunization. The
antigens were diluted to the appropriate concentration in saline and then mixed with aluminum
hydroxide (1.25-mg/ml final concentration [Brenntag]) in 5-ml Eppendorf tubes and incubated at 4°C
overnight with rotation (24 rpm) on a Mini LabRoller (Labnet International, Inc.). Four- to 6-week-old
female mice received three subcutaneous immunizations on the upper back (30 g of total protein per
immunization per mouse in a 200-l volume) 2 weeks apart. Animals were bled under isoflurane
anesthesia 2 weeks after the last immunization for measurement of antibody and analysis of T-cell
responses. The endotoxin concentration in the S. aureus mix and MAPS vaccine were 23 and 11 EU per
dose, respectively, as measured using the Pierce Chromogenic Endotoxin Quant kit (Thermo Scientific).
For passive immunization experiments, we used rabbit antisera, based on the established finding that
rabbit IgG is compatible with mouse Fc receptors (57) and to obtain adequate volumes of sera. Rabbit
anti-S. aureus MAPS sera were generated at Cocalico Biologicals (Reamstown, PA). New Zealand White
rabbits were given three intramuscular immunizations, 2 weeks apart, with S. aureus MAPS vaccine
(300 g of total protein per immunization per rabbit in 500-l volume). Sera were collected before the
first immunization (preimmune sera) and 2 weeks after the last immunization (antisera). Antigen-specific
IgG antibody was detected by enzyme-linked immunosorbent assay (ELISA), and the rabbit serum with
highest antibody titer was used for passive immunization in mice. For passive immunization, 8-week-old
female mice received 200 l of heat-inactivated pre- or postimmune sera 1 day prior to infection via
intraperitoneal injection.
For preparation of inocula, S. aureus strains were streaked onto blood agar plates and grown at 37°C.
Colonies were picked and inoculated into tryptic soy broth (TSB [Sigma]) for an overnight culture. In the
following morning, bacteria were reinoculated into fresh TSB medium at a 1:100 dilution and incubated
at 37°C with shaking. Bacteria were collected 3 h later by centrifugation, washed twice with saline, and
adjusted to the appropriate concentration in saline before infection.
Mice were infected 3 weeks after the last immunization. The bacteremia model was performed using
the ATCC 29213 strain as described previously (58) with minor modifications. Briefly, mice were
anesthetized with isoflurane and injected intravenously with 2  107 CFU in 100 l. Mice were monitored
for any sign of illness for 14 days; any ill-appearing animal (presenting with signs of ruffled fur, slow
moving, and/or with closed eyes) was immediately and humanely euthanized. In the dermonecrosis
model, mice were anesthetized and injected subcutaneously on the shaved lower back with 1  107 CFU
of the USA300 strain in a 100-l volume. Mice were monitored for 14 days after infection. Pictures of the
infected area were taken at different time points, and the sizes of dermonecrotic lesions were measured
using ImageJ software. In the skin abscess model, the backs of mice were shaved, anesthetized, and
infected subcutaneously with 2.5  105 CFU of the USA300 strain in a 100-l volume. Mice were then
humanely euthanized 4 days after infection. Abscesses were dissected and homogenized in 500 l of PBS
using a bead beater. Serial dilutions of homogenate were plated on mannitol salt plates, and colonies
were counted after overnight incubation at 37°C. For animals that were abscess free or for culture-
negative samples, the CFU was arbitrarily set as one-half of the lower detection limit (22.5 CFU) to allow
for statistical analysis. In the GI colonization model (59), mice were gently restrained and inoculated
intranasally with 5  107 CFU of the USA300 LACstrep strain in a 10-l volume. Fecal pellets were collected
on days 1 and 7 after inoculation or as indicated. Samples were weighed, resuspended in sterile PBS at
0.1 g/ml, homogenized, and then passed through a CellTrics 30-m-pore filter. Serial dilutions of the
flowthrough samples were plated on mannitol salt plates containing 0.5 mg/ml streptomycin, and
colonies were counted after overnight culture at 37°C. For culture-negative samples, CFU was set as
one-half of the lower detection limit (40 CFU).
Antibody and T-cell response analysis. Antigen-specific IgG antibody was measured by ELISA using
Immulon 2 HB 96-microwell plates (Thermo Scientific) coated with individual recombinant S. aureus
protein (not containing rhizavidin) (1 g/ml in PBS, incubated at room temperature overnight). The
plates were washed with PBS containing 0.05% Tween 20 (PBS-T) and then blocked with 1% bovine
serum albumin (BSA) in PBS for 1 h. After blocking, serial dilutions of mouse or rabbit sera were added
and incubated for 2 h, followed by a 1-h incubation with horseradish peroxidase (HRP)-conjugated
secondary antibody against mouse or rabbit IgG. The plates were then washed and developed with
SureBlue TMB Microwell peroxidase substrate (KPL). HCl (1 M) was used to terminate the reactions before
the A450 was analyzed using an ELISA reader. A reference serum was generated by pooling sera from 10
mice that have been immunized three times with S. aureus MAPS vaccine. The IgG titer of the reference
serum against each target S. aureus protein was assigned a value of 12,000 arbitrary units per ml.
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Duplicates of 7 serial dilutions of the reference serum were included in each ELISA. The antibody titer of
each sample serum was expressed as calculated arbitrary units per ml using standard curves generated
by dilutions of the reference serum.
Antigen-specific T memory responses were analyzed by ex vivo stimulation of peripheral blood cells
or splenocytes with purified S. aureus protein antigens (representing a recall response). For whole-blood
stimulation, 25 l of heparinized blood from each mouse was added to 225 l Dulbecco’s modified
Eagle’s medium (DMEM [BioWhittaker]) containing 10% low-endotoxin defined fetal bovine serum (FBS
[HyClone]), 50 M 2-mercaptoethanol (Sigma), and ciprofloxacin (10 g/ml [Cellgro]). Cultures were
incubated at 37°C for 6 days in the presence of 2.5 g/ml of the mixture of six S. aureus protein antigens
(equal weight ratio, non-rhizavidin containing). Supernatants were collected following centrifugation and
analyzed by ELISA for IFN- and IL-17A concentrations (R&D Systems). Splenocytes were isolated from
mice in the Alum- or S. aureus MAPS-immunized group. Splenocytes from an S. aureus MAPS-vaccinated
mouse were then divided into two equal fractions, and from each fraction, CD4 or CD8 T cells were
purified using a CD4 or CD8 selection kit from Miltenyi Biotec. For stimulation, 2.25  106 splenocytes
of Alum-vaccinated mouse, alone or mixed with 6  105 purified CD4 T cells or 4  105 CD8 T cells that
originated from an S. aureus MAPS-immunized mouse, were added into each well of a 96-well microplate
(250 l per well) and incubated at 37°C for 3 days in the absence or presence of S. aureus proteins at the
indicated concentrations. Supernatants were then collected and analyzed for cytokine production.
Hemolysis analysis. The hemolytic activity of wild-type Hla and Hla209 and their respective
rhizavidin fusions was measured as follows. Two hundred microliters of heparinized rabbit blood was
washed with cold PBS three times. Red blood cells were then resuspended in 10 ml of cold PBS (2% rabbit
red blood cells), and 100 l of a 2-fold serial dilution of Hla samples in PBS with 0.1% BSA, starting from
100 g/ml, was added to a V-bottom 96-well plate before the addition of 100 l of red blood cells to
each well. PBS containing 0.1% Triton X-100 was used as a positive control (100% hemolysis), and PBS
with 0.1% BSA was used as a negative control (0% hemolysis). The plate was incubated at 37°C for 30 min
and then subjected to centrifugation at 800  g for 5 min. The supernatants were transferred into a
flat-bottom 96-well plate, and the A545 was measured by an ELISA reader. One hemolytic unit (HU) was
defined as the activity that causes 50% lysis of 1% rabbit red blood cells after 30 min of incubation at
37°C. The activity of each Hla construct was expressed as the HU of 1 mg/ml of purified protein.
Statistical analysis. All statistical analyses were done using PRISM (version 5.01 for Windows,
GraphPad Software, Inc.). Survival curves were analyzed by the Mantel-Cox test. Incidence of dermone-
crosis was compared by Fisher’s exact test. Development of dermonecrosis postinfection was compared
by two-way analysis of variance (ANOVA). Cytokine production and CFU counts in abscesses or in feces
were compared using the Mann-Whitney U test (two-tailed), nonparametric one-way ANOVA (Dunn’s
multiple comparison test), or two-way ANOVA, as indicated.
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